US Stock MarketDetailed Quotes

HEWA HEALTHWAREHOUSE.COM INC

Watchlist

0.129400
0.0000000.00%

15min DelayClose May 17 15:14 ET

7.08MMarket Cap-3235P/E (TTM)

HEALTHWAREHOUSE.COM INC Key Stats

Earnings

Revenue Breakdown

Financial Indicators

Income Statement

Balance Sheet

Cash Flow

Quarterly+Annual

YOY

Hide blank lines

(Q1)Mar 31, 2024

(FY)Dec 31, 2023

(Q2)Jun 30, 2023

(Q1)Mar 31, 2023

(FY)Dec 31, 2022

(Q4)Dec 31, 2022

(Q3)Sep 30, 2022

(Q2)Jun 30, 2022

(Q1)Mar 31, 2022

(FY)Dec 31, 2021

Operating Cash Flow (Indirect Method)

Cash flow from continuing operating activities

135.73%47.71K

73.76%-163.84K

-30.78%-229.94K

61.28%-133.54K

-255.92%-624.45K

34.46K

-675.45%-138.18K

-286.21%-175.82K

-293.68%-344.9K

59.65%400.51K

Net income from continuing operations

27.49%-252.41K

-86.29%-1.77M

-62.58%-477.22K

-62.68%-348.12K

-66.29%-952.03K

---218.9K

-24.63%-225.61K

-61.44%-293.52K

-63.32%-213.99K

-189.27%-572.5K

Depreciation and amortization

58.97%104.19K

54.12%346.37K

36.00%74.48K

21.83%65.54K

66.66%224.75K

--124.19K

-123.41%-8.01K

64.56%54.77K

61.66%53.8K

0.96%134.86K

Other non cash items

321.18%41.04K

-66.67%12.99K

4,323.88%430.97K

0.00%9.74K

53.21%38.97K

--9.74K

-15.40%9.74K

-15.41%9.74K

-15.40%9.74K

-32.98%25.44K

Change In working capital

61.10%-32.55K

82.13%-162.6K

-1,018.46%-493.59K

83.16%-83.68K

-1,431.69%-910.03K

---256.52K

-234.38%-112.43K

-213.68%-44.13K

-679.41%-496.95K

137.70%68.34K

-Change in receivables

97.78%-4.55K

73.07%-188.28K

-301.02%-519.66K

-32.25%-204.58K

-812.42%-699.19K

---302.37K

-571.80%-112.55K

-810.18%-129.58K

-292.02%-154.69K

176.73%98.14K

-Change in inventory

43.13%58.62K

83.05%-67.63K

-97.73%2.18K

115.28%40.95K

-722.70%-399.04K

---107.91K

-17.48%-119.14K

7,566.69%95.99K

-6,209.82%-267.98K

-422.93%-48.5K

-Change in prepaid assets

103.55%86.3K

479.91%15.99K

-26.39%46.74K

13.33%42.4K

104.42%2.76K

--70.51K

-35.47%-168.67K

1,050.04%63.5K

114.33%37.41K

-28.56%-62.44K

-Change in payables and accrued expense

-340.43%-146.85K

-35.91%175.61K

102.08%1.09K

167.48%61.08K

237.71%274.02K

--171.82K

17.29%245.19K

-189.73%-52.49K

-1,031.53%-90.51K

509.23%81.14K

-Change in other current liabilities

-10.82%-26.07K

-10.95%-98.27K

-11.10%-23.94K

-11.10%-23.53K

---88.57K

----

---21.55K

---21.18K

--0

Cash from discontinued investing activities

Operating cash flow

135.73%47.71K

73.76%-163.84K

-30.78%-229.94K

61.28%-133.54K

-255.92%-624.45K

--34.46K

-675.45%-138.18K

-286.21%-175.82K

-293.68%-344.9K

59.65%400.51K

Investing cash flow

Cash flow from continuing investing activities

73.35%-55K

39.56%-309.97K

-264.48%-91.58K

-121.71%-206.39K

-490.43%-512.85K

-338.19K

-88.79%-56.44K

-25.13K

-93.09K

-761.72%-86.86K

Capital expenditure reported

--0

76.80%-55.88K

-65.07%-41.48K

-39.21%-129.59K

-177.28%-240.85K

---66.19K

-88.79%-56.44K

---25.13K

---93.09K

-761.72%-86.86K

Net intangibles purchase and sale

--0

6.58%-254.09K

---50.1K

---76.8K

---272K

----

--0

Net other investing changes

---55K

----

Cash from discontinued investing activities

Investing cash flow

73.35%-55K

39.56%-309.97K

-264.48%-91.58K

-121.71%-206.39K

-490.43%-512.85K

---338.19K

-88.79%-56.44K

---25.13K

---93.09K

-761.72%-86.86K

Financing cash flow

Cash flow from continuing financing activities

Cash from discontinued financing activities

Net cash flow

Beginning cash position

-45.48%567.96K

-52.19%1.04M

-59.69%701.83K

-52.19%1.04M

16.81%2.18M

--1.35M

-27.96%1.54M

-14.80%1.74M

16.81%2.18M

74.55%1.87M

Current changes in cash

97.86%-7.29K

58.34%-473.81K

-60.00%-321.51K

22.39%-339.94K

-462.61%-1.14M

---303.74K

-3,208.26%-194.63K

-312.82%-200.95K

-345.96%-437.99K

-60.63%313.65K

End cash Position

-20.11%560.67K

-45.48%567.96K

-75.31%380.32K

-59.69%701.83K

-52.19%1.04M

--1.04M

-36.89%1.35M

-27.96%1.54M

-14.80%1.74M

16.81%2.18M

Free cash flow

114.04%47.71K

58.34%-473.81K

-60.00%-321.51K

22.39%-339.94K

-462.61%-1.14M

---303.74K

-3,208.26%-194.63K

-312.82%-200.95K

-345.96%-437.99K

30.26%313.65K

Currency Unit

USD

Accounting Standards

US-GAAP

Audit Opinions

Unqualified Opinion

	(Q1)Mar 31, 2024	(FY)Dec 31, 2023	(Q2)Jun 30, 2023	(Q1)Mar 31, 2023	(FY)Dec 31, 2022	(Q4)Dec 31, 2022	(Q3)Sep 30, 2022	(Q2)Jun 30, 2022	(Q1)Mar 31, 2022	(FY)Dec 31, 2021
Operating Cash Flow (Indirect Method)
Cash flow from continuing operating activities	135.73%47.71K	73.76%-163.84K	-30.78%-229.94K	61.28%-133.54K	-255.92%-624.45K	34.46K	-675.45%-138.18K	-286.21%-175.82K	-293.68%-344.9K	59.65%400.51K
Net income from continuing operations	27.49%-252.41K	-86.29%-1.77M	-62.58%-477.22K	-62.68%-348.12K	-66.29%-952.03K	---218.9K	-24.63%-225.61K	-61.44%-293.52K	-63.32%-213.99K	-189.27%-572.5K
Depreciation and amortization	58.97%104.19K	54.12%346.37K	36.00%74.48K	21.83%65.54K	66.66%224.75K	--124.19K	-123.41%-8.01K	64.56%54.77K	61.66%53.8K	0.96%134.86K
Other non cash items	321.18%41.04K	-66.67%12.99K	4,323.88%430.97K	0.00%9.74K	53.21%38.97K	--9.74K	-15.40%9.74K	-15.41%9.74K	-15.40%9.74K	-32.98%25.44K
Change In working capital	61.10%-32.55K	82.13%-162.6K	-1,018.46%-493.59K	83.16%-83.68K	-1,431.69%-910.03K	---256.52K	-234.38%-112.43K	-213.68%-44.13K	-679.41%-496.95K	137.70%68.34K
-Change in receivables	97.78%-4.55K	73.07%-188.28K	-301.02%-519.66K	-32.25%-204.58K	-812.42%-699.19K	---302.37K	-571.80%-112.55K	-810.18%-129.58K	-292.02%-154.69K	176.73%98.14K
-Change in inventory	43.13%58.62K	83.05%-67.63K	-97.73%2.18K	115.28%40.95K	-722.70%-399.04K	---107.91K	-17.48%-119.14K	7,566.69%95.99K	-6,209.82%-267.98K	-422.93%-48.5K
-Change in prepaid assets	103.55%86.3K	479.91%15.99K	-26.39%46.74K	13.33%42.4K	104.42%2.76K	--70.51K	-35.47%-168.67K	1,050.04%63.5K	114.33%37.41K	-28.56%-62.44K
-Change in payables and accrued expense	-340.43%-146.85K	-35.91%175.61K	102.08%1.09K	167.48%61.08K	237.71%274.02K	--171.82K	17.29%245.19K	-189.73%-52.49K	-1,031.53%-90.51K	509.23%81.14K
-Change in other current liabilities	-10.82%-26.07K	-10.95%-98.27K	-11.10%-23.94K	-11.10%-23.53K	---88.57K	----	----	---21.55K	---21.18K	--0
Cash from discontinued investing activities
Operating cash flow	135.73%47.71K	73.76%-163.84K	-30.78%-229.94K	61.28%-133.54K	-255.92%-624.45K	--34.46K	-675.45%-138.18K	-286.21%-175.82K	-293.68%-344.9K	59.65%400.51K
Investing cash flow
Cash flow from continuing investing activities	73.35%-55K	39.56%-309.97K	-264.48%-91.58K	-121.71%-206.39K	-490.43%-512.85K	-338.19K	-88.79%-56.44K	-25.13K	-93.09K	-761.72%-86.86K
Capital expenditure reported	--0	76.80%-55.88K	-65.07%-41.48K	-39.21%-129.59K	-177.28%-240.85K	---66.19K	-88.79%-56.44K	---25.13K	---93.09K	-761.72%-86.86K
Net intangibles purchase and sale	--0	6.58%-254.09K	---50.1K	---76.8K	---272K	----	----	--0	--0	--0
Net other investing changes	---55K	----	----	----	----	----	----	----	----	----
Cash from discontinued investing activities
Investing cash flow	73.35%-55K	39.56%-309.97K	-264.48%-91.58K	-121.71%-206.39K	-490.43%-512.85K	---338.19K	-88.79%-56.44K	---25.13K	---93.09K	-761.72%-86.86K
Financing cash flow
Cash flow from continuing financing activities
Cash from discontinued financing activities
Net cash flow
Beginning cash position	-45.48%567.96K	-52.19%1.04M	-59.69%701.83K	-52.19%1.04M	16.81%2.18M	--1.35M	-27.96%1.54M	-14.80%1.74M	16.81%2.18M	74.55%1.87M
Current changes in cash	97.86%-7.29K	58.34%-473.81K	-60.00%-321.51K	22.39%-339.94K	-462.61%-1.14M	---303.74K	-3,208.26%-194.63K	-312.82%-200.95K	-345.96%-437.99K	-60.63%313.65K
End cash Position	-20.11%560.67K	-45.48%567.96K	-75.31%380.32K	-59.69%701.83K	-52.19%1.04M	--1.04M	-36.89%1.35M	-27.96%1.54M	-14.80%1.74M	16.81%2.18M
Free cash flow	114.04%47.71K	58.34%-473.81K	-60.00%-321.51K	22.39%-339.94K	-462.61%-1.14M	---303.74K	-3,208.26%-194.63K	-312.82%-200.95K	-345.96%-437.99K	30.26%313.65K
Currency Unit	USD	USD	USD	USD	USD	USD	USD	USD	USD	USD
Accounting Standards	US-GAAP	US-GAAP	US-GAAP	US-GAAP	US-GAAP	US-GAAP	US-GAAP	US-GAAP	US-GAAP	US-GAAP
Audit Opinions	--	Unqualified Opinion	--	--	Unqualified Opinion	--	--	--	--	Unqualified Opinion

Analysis

Analyst Rating

No Data

Price Target

No Data

Heat List

Overall